Artículo Original 140.- Boero MBE, Morgando A, Verme G. 100 Treatment of pseudomembranous colitis: a randomized controlled trial with rifaximin vs vancomycin. Microbiol Med 1990; 5: 74-7. 141.- Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, et al. A randomized, double-blind, placebocontrolled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011; 66: 2850-5. 142.- El-Herte RI, Baban TA, Kanj SS. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. Scand J Infect Dis 2012; 44: 228-30. 143.- Garey K W, Salazar M, Shah D, Rodrigue R, Dupont H L. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 2008; 42: 827-35. 144.- Gerding DN, Muto CA, Owens RC, Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S32-42. 145.- Neff G W, Jones M, Jonas M, Ravinuthala R, Novick D, Kaiser TE, et al. Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: CONSENSO CHILENO DIARREA ASOCIADA A CLOSTRIDIUM DIFFICILE - C. Hernández-Rocha et al. a retrospective analysis. J Clin Gastroenterol 2013; 47: 188-92. 146.- Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2013; 37: 122-8. 147.- Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44: 846-8. 148.- Cocanour CS. Best strategies in recurrent or persistent Clostridium difficile infection. Surg Infect 2011; 12: 235-9. 149.- van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-15. 150.- Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014; 58: 1515-22. 151.- Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 994-1002. 152.- Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014; 48: 693-702. 153.- Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500-8. 154.- Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman L A. Systematic review: faecal transplantation for the treatment of Clostridium difficileassociated disease. Aliment Pharmacol Ther 2012; 35: 865-75. 155.- Bakken J S, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9: 1044-9. 156.- Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-60. Gastroenterol. latinoam 2016; Vol 27, Nº 2: 79-100
gastro 2 2016
To see the actual publication please follow the link above